Adeshwar Meditex Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: July 22, 2025, 9:30 pm

Quick Insight

Adeshwar Meditex Ltd's current market cap stands at ₹26.0 Cr. with a P/E ratio of 12.6, reflecting a moderate valuation in the Medical Equipment & Accessories industry. The company's Return on Equity (ROE) at 5.76% and Return on Capital Employed (ROCE) at 8.39% indicate room for improvement in operational efficiency and capital utilization. While the profit margins are relatively low at 5.82%, the company's solid reserve of ₹22.53 Cr. and manageable debt level of ₹12.46 Cr. with an Interest Coverage Ratio (ICR) of 3.47x provide a stable financial base. However, the low Price-to-Book Value (P/BV) ratio of 0.65x suggests potential undervaluation, offering an opportunity for investors to consider the stock for long-term growth prospects in the medical equipment sector.

Competitors of Adeshwar Meditex Ltd

All Competitor Stocks of Adeshwar Meditex Ltd

Quarterly Result

Last Updated: May 31, 2025, 7:10 am

Below is a detailed analysis of the quarterly data for Adeshwar Meditex Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 37.45 Cr.. The value appears to be declining and may need further review. It has decreased from 40.90 Cr. (Sep 2024) to 37.45 Cr., marking a decrease of 3.45 Cr..
• For Expenses, as of Mar 2025, the value is 35.27 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 38.90 Cr. (Sep 2024) to 35.27 Cr., marking a decrease of 3.63 Cr..
• For Operating Profit, as of Mar 2025, the value is 2.18 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Sep 2024) to 2.18 Cr., marking an increase of 0.18 Cr..
• For OPM %, as of Mar 2025, the value is 5.82%. The value appears strong and on an upward trend. It has increased from 4.89% (Sep 2024) to 5.82%, marking an increase of 0.93%.
• For Other Income, as of Mar 2025, the value is 0.17 Cr.. The value appears to be declining and may need further review. It has decreased from 0.21 Cr. (Sep 2024) to 0.17 Cr., marking a decrease of 0.04 Cr..
• For Interest, as of Mar 2025, the value is 0.31 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.71 Cr. (Sep 2024) to 0.31 Cr., marking a decrease of 0.40 Cr..
• For Depreciation, as of Mar 2025, the value is 0.21 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.25 Cr. (Sep 2024) to 0.21 Cr., marking a decrease of 0.04 Cr..
• For Profit before tax, as of Mar 2025, the value is 1.83 Cr.. The value appears strong and on an upward trend. It has increased from 1.25 Cr. (Sep 2024) to 1.83 Cr., marking an increase of 0.58 Cr..
• For Tax %, as of Mar 2025, the value is 27.32%. The value appears to be improving (decreasing) as expected. It has decreased from 28.00% (Sep 2024) to 27.32%, marking a decrease of 0.68%.
• For Net Profit, as of Mar 2025, the value is 1.34 Cr.. The value appears strong and on an upward trend. It has increased from 0.90 Cr. (Sep 2024) to 1.34 Cr., marking an increase of 0.44 Cr..
• For EPS in Rs, as of Mar 2025, the value is 0.93. The value appears strong and on an upward trend. It has increased from 0.62 (Sep 2024) to 0.93, marking an increase of 0.31.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 3:15 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 1:59 pm

Below is a detailed analysis of the balance sheet data for Adeshwar Meditex Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 14.43 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 14.43 Cr..
• For Reserves, as of Mar 2025, the value is 22.53 Cr.. The value appears strong and on an upward trend. It has increased from 20.48 Cr. (Mar 2024) to 22.53 Cr., marking an increase of 2.05 Cr..
• For Borrowings, as of Mar 2025, the value is 12.46 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 13.89 Cr. (Mar 2024) to 12.46 Cr., marking a decrease of 1.43 Cr..
• For Other Liabilities, as of Mar 2025, the value is 22.78 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15.23 Cr. (Mar 2024) to 22.78 Cr., marking an increase of 7.55 Cr..
• For Total Liabilities, as of Mar 2025, the value is 72.20 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 64.03 Cr. (Mar 2024) to 72.20 Cr., marking an increase of 8.17 Cr..
• For Fixed Assets, as of Mar 2025, the value is 2.95 Cr.. The value appears to be declining and may need further review. It has decreased from 3.53 Cr. (Mar 2024) to 2.95 Cr., marking a decrease of 0.58 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.10 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 0.10 Cr..
• For Other Assets, as of Mar 2025, the value is 69.25 Cr.. The value appears strong and on an upward trend. It has increased from 60.40 Cr. (Mar 2024) to 69.25 Cr., marking an increase of 8.85 Cr..
• For Total Assets, as of Mar 2025, the value is 72.20 Cr.. The value appears strong and on an upward trend. It has increased from 64.03 Cr. (Mar 2024) to 72.20 Cr., marking an increase of 8.17 Cr..

Notably, the Reserves (22.53 Cr.) exceed the Borrowings (12.46 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Adeshwar Meditex Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 5. It has increased from 1.39 (Mar 24) to 1.43, marking an increase of 0.04.
• For Diluted EPS (Rs.), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 5. It has increased from 1.39 (Mar 24) to 1.43, marking an increase of 0.04.
• For Cash EPS (Rs.), as of Mar 25, the value is 1.64. This value is below the healthy minimum of 3. It has decreased from 1.81 (Mar 24) to 1.64, marking a decrease of 0.17.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 25.61. It has increased from 24.19 (Mar 24) to 25.61, marking an increase of 1.42.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 25.61. It has increased from 24.19 (Mar 24) to 25.61, marking an increase of 1.42.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 58.01. It has increased from 55.33 (Mar 24) to 58.01, marking an increase of 2.68.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 3.21. This value is within the healthy range. It has decreased from 3.68 (Mar 24) to 3.21, marking a decrease of 0.47.
• For PBIT / Share (Rs.), as of Mar 25, the value is 2.86. This value is within the healthy range. It has decreased from 3.26 (Mar 24) to 2.86, marking a decrease of 0.40.
• For PBT / Share (Rs.), as of Mar 25, the value is 1.94. This value is within the healthy range. It has increased from 1.93 (Mar 24) to 1.94, marking an increase of 0.01.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 1.30. This value is below the healthy minimum of 2. It has decreased from 1.39 (Mar 24) to 1.30, marking a decrease of 0.09.
• For PBDIT Margin (%), as of Mar 25, the value is 5.52. This value is below the healthy minimum of 10. It has decreased from 6.64 (Mar 24) to 5.52, marking a decrease of 1.12.
• For PBIT Margin (%), as of Mar 25, the value is 4.93. This value is below the healthy minimum of 10. It has decreased from 5.89 (Mar 24) to 4.93, marking a decrease of 0.96.
• For PBT Margin (%), as of Mar 25, the value is 3.33. This value is below the healthy minimum of 10. It has decreased from 3.48 (Mar 24) to 3.33, marking a decrease of 0.15.
• For Net Profit Margin (%), as of Mar 25, the value is 2.23. This value is below the healthy minimum of 5. It has decreased from 2.51 (Mar 24) to 2.23, marking a decrease of 0.28.
• For Return on Networth / Equity (%), as of Mar 25, the value is 5.06. This value is below the healthy minimum of 15. It has decreased from 5.75 (Mar 24) to 5.06, marking a decrease of 0.69.
• For Return on Capital Employeed (%), as of Mar 25, the value is 10.49. This value is within the healthy range. It has decreased from 12.96 (Mar 24) to 10.49, marking a decrease of 2.47.
• For Return On Assets (%), as of Mar 25, the value is 2.59. This value is below the healthy minimum of 5. It has decreased from 3.13 (Mar 24) to 2.59, marking a decrease of 0.54.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. It has increased from 0.03 (Mar 24) to 0.05, marking an increase of 0.02.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.33. This value is within the healthy range. It has decreased from 0.39 (Mar 24) to 0.33, marking a decrease of 0.06.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.23. It has increased from 1.22 (Mar 24) to 1.23, marking an increase of 0.01.
• For Current Ratio (X), as of Mar 25, the value is 2.03. This value is within the healthy range. It has decreased from 2.06 (Mar 24) to 2.03, marking a decrease of 0.03.
• For Quick Ratio (X), as of Mar 25, the value is 1.25. This value is within the healthy range. It has increased from 1.10 (Mar 24) to 1.25, marking an increase of 0.15.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.81. This value is below the healthy minimum of 4. It has decreased from 2.86 (Mar 24) to 2.81, marking a decrease of 0.05.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 3.47. This value is within the healthy range. It has increased from 2.76 (Mar 24) to 3.47, marking an increase of 0.71.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.40. This value is below the healthy minimum of 3. It has increased from 2.04 (Mar 24) to 2.40, marking an increase of 0.36.
• For Enterprise Value (Cr.), as of Mar 25, the value is 33.89. It has decreased from 60.21 (Mar 24) to 33.89, marking a decrease of 26.32.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.40. This value is below the healthy minimum of 1. It has decreased from 0.75 (Mar 24) to 0.40, marking a decrease of 0.35.
• For EV / EBITDA (X), as of Mar 25, the value is 7.33. This value is within the healthy range. It has decreased from 11.34 (Mar 24) to 7.33, marking a decrease of 4.01.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 1. It has decreased from 0.59 (Mar 24) to 0.28, marking a decrease of 0.31.
• For Price / BV (X), as of Mar 25, the value is 0.65. This value is below the healthy minimum of 1. It has decreased from 1.36 (Mar 24) to 0.65, marking a decrease of 0.71.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 1. It has decreased from 0.59 (Mar 24) to 0.28, marking a decrease of 0.31.
• For EarningsYield, as of Mar 25, the value is 0.07. This value is below the healthy minimum of 5. It has increased from 0.04 (Mar 24) to 0.07, marking an increase of 0.03.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness